| Sameer Goel, | |
|
659 Douglas Ave, Altamonte Springs, FL 32714-2509 | |
| (407) 287-5240 | |
| (407) 214-3120 |
| Full Name | Sameer Goel |
|---|---|
| Gender | Male |
| Speciality | Pain Management |
| Experience | 7 Years |
| Location | 659 Douglas Ave, Altamonte Springs, Florida |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1073044897 | NPI | - | NPPES |
| Facility Name | Location | Facility Type |
|---|---|---|
| Sentara Williamsburg Regional Medical Center | Williamsburg, VA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Jacksonville Spine Center Pa | 6901890300 | 41 |
| Premier Anesthesia Of Virginia Llc | 1951722362 | 40 |
News Archive
Edwards Lifesciences Corporation (NYSE: EW), the world leader in the science of heart valves, announced today the first successful clinical use of its new lower-profile Ascendra 2 transapical delivery system, designed to benefit both patients and physicians by minimizing trauma and blood loss, and facilitating transcatheter heart valve delivery and deployment.
Enzo Biochem, Inc. (NYSE: ENZ), announced today that it had entered into a Cooperative Research and Development Agreement (CRADA) with the National Eye Institute, part of the National Institute of Health, to conduct a human clinical trial of Optiquel™, Enzo's oral, proprietary therapeutic for chronic autoimmune uveitis.
In this week's PLoS Medicine, Abdullah Baqui from the Johns Hopkins Bloomberg School of Public Health, USA and colleagues systematically review studies describing newborn care-seeking behaviours by caregivers in low- and middle-income countries.
Oncotarget Volume 11, Issue 34 features Figure 1, "BRAF inhibitor-induced changes in cell viability," by Pickles, et al which reported that the BEACON CRC trial demonstrated a survival advantage over chemotherapy for a combination of targeted agents comprising the potent BRAF inhibitor encorafenib together with cetuximab and binimetinib.
› Verified 9 days ago
| Entity Name | Us Anesthesia Partners Of Florida Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1518910520 PECOS PAC ID: 0345143152 Enrollment ID: O20040129000594 |
News Archive
Edwards Lifesciences Corporation (NYSE: EW), the world leader in the science of heart valves, announced today the first successful clinical use of its new lower-profile Ascendra 2 transapical delivery system, designed to benefit both patients and physicians by minimizing trauma and blood loss, and facilitating transcatheter heart valve delivery and deployment.
Enzo Biochem, Inc. (NYSE: ENZ), announced today that it had entered into a Cooperative Research and Development Agreement (CRADA) with the National Eye Institute, part of the National Institute of Health, to conduct a human clinical trial of Optiquel™, Enzo's oral, proprietary therapeutic for chronic autoimmune uveitis.
In this week's PLoS Medicine, Abdullah Baqui from the Johns Hopkins Bloomberg School of Public Health, USA and colleagues systematically review studies describing newborn care-seeking behaviours by caregivers in low- and middle-income countries.
Oncotarget Volume 11, Issue 34 features Figure 1, "BRAF inhibitor-induced changes in cell viability," by Pickles, et al which reported that the BEACON CRC trial demonstrated a survival advantage over chemotherapy for a combination of targeted agents comprising the potent BRAF inhibitor encorafenib together with cetuximab and binimetinib.
› Verified 9 days ago
| Entity Name | Jacksonville Spine Center Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1881643757 PECOS PAC ID: 6901890300 Enrollment ID: O20040408001580 |
News Archive
Edwards Lifesciences Corporation (NYSE: EW), the world leader in the science of heart valves, announced today the first successful clinical use of its new lower-profile Ascendra 2 transapical delivery system, designed to benefit both patients and physicians by minimizing trauma and blood loss, and facilitating transcatheter heart valve delivery and deployment.
Enzo Biochem, Inc. (NYSE: ENZ), announced today that it had entered into a Cooperative Research and Development Agreement (CRADA) with the National Eye Institute, part of the National Institute of Health, to conduct a human clinical trial of Optiquel™, Enzo's oral, proprietary therapeutic for chronic autoimmune uveitis.
In this week's PLoS Medicine, Abdullah Baqui from the Johns Hopkins Bloomberg School of Public Health, USA and colleagues systematically review studies describing newborn care-seeking behaviours by caregivers in low- and middle-income countries.
Oncotarget Volume 11, Issue 34 features Figure 1, "BRAF inhibitor-induced changes in cell viability," by Pickles, et al which reported that the BEACON CRC trial demonstrated a survival advantage over chemotherapy for a combination of targeted agents comprising the potent BRAF inhibitor encorafenib together with cetuximab and binimetinib.
› Verified 9 days ago
| Entity Name | Anesthesiologists Of Greater Orlando Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1457300998 PECOS PAC ID: 7416928536 Enrollment ID: O20040803000929 |
News Archive
Edwards Lifesciences Corporation (NYSE: EW), the world leader in the science of heart valves, announced today the first successful clinical use of its new lower-profile Ascendra 2 transapical delivery system, designed to benefit both patients and physicians by minimizing trauma and blood loss, and facilitating transcatheter heart valve delivery and deployment.
Enzo Biochem, Inc. (NYSE: ENZ), announced today that it had entered into a Cooperative Research and Development Agreement (CRADA) with the National Eye Institute, part of the National Institute of Health, to conduct a human clinical trial of Optiquel™, Enzo's oral, proprietary therapeutic for chronic autoimmune uveitis.
In this week's PLoS Medicine, Abdullah Baqui from the Johns Hopkins Bloomberg School of Public Health, USA and colleagues systematically review studies describing newborn care-seeking behaviours by caregivers in low- and middle-income countries.
Oncotarget Volume 11, Issue 34 features Figure 1, "BRAF inhibitor-induced changes in cell viability," by Pickles, et al which reported that the BEACON CRC trial demonstrated a survival advantage over chemotherapy for a combination of targeted agents comprising the potent BRAF inhibitor encorafenib together with cetuximab and binimetinib.
› Verified 9 days ago
| Entity Name | Sunshine Interventional Pain And Wellness Center Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1669123113 PECOS PAC ID: 6800279191 Enrollment ID: O20220819000230 |
News Archive
Edwards Lifesciences Corporation (NYSE: EW), the world leader in the science of heart valves, announced today the first successful clinical use of its new lower-profile Ascendra 2 transapical delivery system, designed to benefit both patients and physicians by minimizing trauma and blood loss, and facilitating transcatheter heart valve delivery and deployment.
Enzo Biochem, Inc. (NYSE: ENZ), announced today that it had entered into a Cooperative Research and Development Agreement (CRADA) with the National Eye Institute, part of the National Institute of Health, to conduct a human clinical trial of Optiquel™, Enzo's oral, proprietary therapeutic for chronic autoimmune uveitis.
In this week's PLoS Medicine, Abdullah Baqui from the Johns Hopkins Bloomberg School of Public Health, USA and colleagues systematically review studies describing newborn care-seeking behaviours by caregivers in low- and middle-income countries.
Oncotarget Volume 11, Issue 34 features Figure 1, "BRAF inhibitor-induced changes in cell viability," by Pickles, et al which reported that the BEACON CRC trial demonstrated a survival advantage over chemotherapy for a combination of targeted agents comprising the potent BRAF inhibitor encorafenib together with cetuximab and binimetinib.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Sameer Goel, 5191 First Coast Tech Pkwy Fl 3, Jacksonville, FL 32224-0609 Ph: (904) 223-3321 | Sameer Goel, 659 Douglas Ave, Altamonte Springs, FL 32714-2509 Ph: (407) 287-5240 |
News Archive
Edwards Lifesciences Corporation (NYSE: EW), the world leader in the science of heart valves, announced today the first successful clinical use of its new lower-profile Ascendra 2 transapical delivery system, designed to benefit both patients and physicians by minimizing trauma and blood loss, and facilitating transcatheter heart valve delivery and deployment.
Enzo Biochem, Inc. (NYSE: ENZ), announced today that it had entered into a Cooperative Research and Development Agreement (CRADA) with the National Eye Institute, part of the National Institute of Health, to conduct a human clinical trial of Optiquel™, Enzo's oral, proprietary therapeutic for chronic autoimmune uveitis.
In this week's PLoS Medicine, Abdullah Baqui from the Johns Hopkins Bloomberg School of Public Health, USA and colleagues systematically review studies describing newborn care-seeking behaviours by caregivers in low- and middle-income countries.
Oncotarget Volume 11, Issue 34 features Figure 1, "BRAF inhibitor-induced changes in cell viability," by Pickles, et al which reported that the BEACON CRC trial demonstrated a survival advantage over chemotherapy for a combination of targeted agents comprising the potent BRAF inhibitor encorafenib together with cetuximab and binimetinib.
› Verified 9 days ago
Juliet Dana Burry, M.D. Pain Medicine Medicare: Accepting Medicare Assignments Practice Location: 499 E Central Pkwy, Suite 115, Altamonte Springs, FL 32701 Phone: 407-671-5115 Fax: 407-671-5116 |